Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Amortization of Deferred Charges (2016 - 2025)

Ironwood Pharmaceuticals' Amortization of Deferred Charges history spans 13 years, with the latest figure at $418000.0 for Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges rose 0.72% year-over-year to $418000.0; the TTM value through Dec 2025 reached $1.7 million, down 12.39%, while the annual FY2025 figure was $1.7 million, 12.39% down from the prior year.
  • Amortization of Deferred Charges for Q4 2025 was $418000.0 at Ironwood Pharmaceuticals, roughly flat from $418000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $6.1 million in Q4 2021 and bottomed at $350000.0 in Q3 2024.
  • The 5-year median for Amortization of Deferred Charges is $500500.0 (2022), against an average of $1.6 million.
  • The largest annual shift saw Amortization of Deferred Charges plummeted 93.49% in 2022 before it surged 46.75% in 2023.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $6.1 million in 2021, then tumbled by 93.49% to $400000.0 in 2022, then soared by 46.75% to $587000.0 in 2023, then fell by 29.3% to $415000.0 in 2024, then rose by 0.72% to $418000.0 in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Amortization of Deferred Charges are $418000.0 (Q4 2025), $418000.0 (Q3 2025), and $416000.0 (Q2 2025).